Intrathecal Therapy for Severe Chronic Pain

From Evidence-Based Recommendations to Practical Recommendations and Demonstrations

Course Description

Chronic pain affects 100 million Americans. Certain patients with chronic pain are candidates for intrathecal (IT) therapy, which can mitigate some of the risks associated with systemic opioids. Following appropriate patient selection based on medical and psychiatric history and a physical exam, a patient can begin a trial with morphine or ziconotide, the 2 US Food and Drug Administration (FDA)–approved IT therapies. Monitoring for adverse events should continue after IT pump implantation, as should monitoring for catheter- or pump-related complications. This CME/CE-accredited Point of Care 201™ 2-part series discusses identification of candidates for IT therapy, available IT therapies, optimal treatment initiation and management, and both surgical implantation and pump refill techniques.

This activity has been supported by an independent educational grant from Jazz Pharmaceuticals.

 

Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications

Image POC201
Intrathecal Therapy for Severe Chronic Pain: Evidence-Based Recommendations

Module 1

Timothy R. Deer, MD, DABPM; Yeshvant A. Navalgund, MD
MODULE 1
Begin Activity

credit amount 0.50

credit type CME/CE

expiration 01/30/2020

Image POC201
Practical Recommendations and Demonstrations

Module 2

Timothy R. Deer, MD, DABPM; Yeshvant A. Navalgund, MD
MODULE 2
Begin Activity

credit amount 0.50

credit type CME/CE

expiration 03/15/2020

Resource

Clinical Issues in Chronic Pain

Debates and Discussions About Therapeutically Targeting Nerve Growth Factor Signaling